Ventricular Dysfunction Clinical Trial
— CADUCEUSOfficial title:
A Phase I Randomized, Dose Escalation Study of the Safety and Efficacy of Intracoronary Delivery of Cardiosphere-Derived Stem Cells in Patients With Ischemic Left Ventricular Dysfunction and a Recent Myocardial Infarction
Verified date | February 2012 |
Source | Cedars-Sinai Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study is to determine whether giving cardiosphere-derived stem cells
(CDCs) to patients with decreased heart function and/or a large amount of damaged muscle
after a heart attack is safe. CDCs are cells grown from small biopsy samples taken from the
heart. Giving a patient their own CDCs is an investigational procedure that has been
approved by the Food and Drug Administration for this study. In addition to determining
whether this treatment is safe, the study will also examine whether it can decrease the
amount of heart muscle damage and/or improve heart function after a heart attack. The amount
of heart muscle damage and the function of the heart directly affects prognosis (the
predicted course of the disease), and the development of heart failure and other
complications some patients experience after a heart attack.
By way of background, scientists and physicians believed, until just a few years ago, that
heart muscle damaged after a heart attack could not be replaced. Recently, however,
scientists discovered that new heart muscle can form, or be regenerated, and that this
process can be enhanced (or increased) by the administration of large numbers of certain
cells isolated from the heart or bone marrow. These cells can be stem cells, or cells
derived from stem cells, and they may achieve their benefit by forming new heart muscle
cells, becoming heart muscle cells themselves, or releasing substances which increase the
ability of already existing stem cells to form new heart muscle. All of the studies
conducted so far have been experimental and no cell type is approved for routine clinical
care of patients with heart disease. However, studies involving bone marrow stem cells do
indicate some small improvement in heart function and one large study demonstrated a
decrease in clinical events in the group which received bone marrow cells.
Investigators of this study decided to study CDCs because they come from a person's own
body, and therefore have no foreign immune antigens which may be rejected. Since the cells
come from the person's heart, they are more likely to form heart tissue. In addition, animal
studies indicate no safety problems and that these cells are capable of forming heart muscle
and blood vessel cells after heart attacks. The investigators are now studying whether the
same is true in humans.
Status | Completed |
Enrollment | 31 |
Est. completion date | February 2012 |
Est. primary completion date | August 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria - Myocardial infarction due to coronary artery atherosclerotic disease. Myocardial infarction will be defined by a rise in serum troponin I to greater than the 99th percentile of the upper limits of normal with at least one of the following: - symptoms of ischemia - ECG changes indicative of new ischemia (new ST-T changes or new left bundle branch block) - development of pathological Q waves on the ECG - imaging evidence of new loss of viable myocardium, OR - new regional wall motion abnormality. - An area of regional dysfunction, i.e., hypokinetic, akinetic, or dyskinetic, as assessed by echocardiography, left ventriculography, or MRI. - History of successful angioplasty and stent placement, with resultant TIMI grade flow = 2, in the artery supplying the infarcted, dysfunctional territory and through which the cells will be infused. - Left ventricular ejection fraction of = .25 and = .45 as determined by clinically-indicated assessment of cardiac function (echocardiogram, gated blood pool scan, x-ray contrast ventriculography, CT and/or MRI one day or more following successful reperfusion). - No further revascularization clinically indicated at the time the patient is assessed for participation in the clinical trial. This will be determined by a cardiologist who is not an investigator in the clinical trial. No further revascularization may be indicated by no arteries with significant stenosis, the location, and extent of any stenosis may not be suitable for angioplasty, the distal vessels may not be suitable for placement of bypass grafts, and/or the patient declines angioplasty or bypass surgery. - Ability to provide informed consent and follow-up with protocol procedures. - Age > 18 years. Exclusion Criteria: - Non-cardiovascular disease with expected life expectancy of < 3 years. - Contraindications to MRI, including: - prior ICD placement - estimated glomerular filtration rate < 50 ml/min - known reaction to gadolinium - claustrophobia - pacemaker - ear implant, and cochlear implant. - History of possible presence of ferromagnetic material including programmable shunt, shrapnel, penile prosthesis, intra-uterine device, bullets, tattoos, artificial limb, blood vessel coil, and tissue expander may require special screening. - Septal infarction involving the right ventricular endocardium as demonstrated by screening MRI (because its presence might increase the potential risk of septal biopsy and decrease treatment benefit due to decreased viability of injured septal-based stem cells). - History of cardiac tumor, or cardiac tumor demonstrated on MRI. - Requirement for chronic immunosuppressive therapy. - Participation in an on-going protocol studying an experimental drug or device. - Diagnosis of right ventricular arrhythmogenic dysplasia. - Patients with occlusion of the infarct-related artery before administration of the study agent. - Current alcohol abuse. - Current drug abuse. - Pregnancy. - Child-bearing potential without use of effective contraception. Men intending to "father" children are also excluded. - Human Immunodeficiency virus infection. - Viral hepatitis. - Uncontrolled diabetes and/or hemoglobin A1C > 8.5%. - Abnormal liver function (SGPT > 3 times the upper reference range) and hematology (hematocrit < 25%, WBC < 3000, platelets < 100,000) studies without a reversible, identifiable cause. - Ventricular tachycardia or fibrillation not associated with an acute ischemic episode. - New York Heart Association Class 4 congestive heart failure. - Canadian Cardiovascular Society Angina Class 3 or 4. - Evidence of tumor on screening chest/abdominal/pelvic (body) CT scan. - Symptomatic ventricular tachyarrhythmia complicating the index myocardial infarction. - Individuals who are not fluent in English. |
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Johns Hopkins Hospital | Baltimore | Maryland |
United States | Cedars-Sinai Medical Center | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
Cedars-Sinai Medical Center | Johns Hopkins University, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), The EMMES Corporation |
United States,
Makkar RR, Smith RR, Cheng K, Malliaras K, Thomson LE, Berman D, Czer LS, Marbán L, Mendizabal A, Johnston PV, Russell SD, Schuleri KH, Lardo AC, Gerstenblith G, Marbán E. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial in — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary objective is to demonstrate the safety of autologous cardiosphere-derived stem cells administered by intra-coronary infusion in patients with ischemic left ventricular dysfunction and a recent myocardial infarction. | 6 months | Yes | |
Secondary | The secondary objective is to demonstrate the efficacy of autologous cardiosphere-derived cells administered by intra-coronary infusion in patients with ischemic left ventricular dysfunction and a recent myocardial infarction. | 12 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03799133 -
Safety and Efficacy of the Gastric Reactance (XL) in Patients Post-operated of Elective Cardiac Surgery
|
N/A | |
Not yet recruiting |
NCT02784912 -
Biomarkers in Risk Stratification of Sustainted Ventricular Tachycardia or Electrical Storm After Ablation
|
N/A | |
Completed |
NCT01673230 -
Hemodynamic Indices Predictive of a Beneficial Response to Fluid Expansion in Case of Hemodynamic Failure After Cardiac Surgery With Altered Preoperative Ejection Fraction (LVEF≤45%)
|
N/A | |
Completed |
NCT00982397 -
Safety and Clinical Performance of the Protecta ICD and CRT-D
|
N/A | |
Completed |
NCT00187252 -
Mascot Study: Management of Atrial Fibrillation (AF) Suppression in AF-Heart Failure (HF) COmorbidity Therapy
|
N/A | |
Recruiting |
NCT04848844 -
The PAtients pResenTing With COngenital HeaRt DIseAse Register (ARTORIA-R)
|
||
Recruiting |
NCT05851053 -
Breast Cancer Long-term Outcomes on Cardiac Functioning: a Longitudinal Study
|
||
Recruiting |
NCT02644850 -
Comparison of Gated Blood-pool SPECT and Echocardiogram for Ventricular Function
|
N/A | |
Terminated |
NCT00524862 -
Standard Drug Therapy vs. Implanted Defibrillator for Primary Prevention of Sudden Cardiac Death
|
N/A | |
Completed |
NCT00526162 -
ConsultaTM CRT-D Clinical Evaluation Study
|
N/A | |
Withdrawn |
NCT00166010 -
Effects of Nesiritide in Pediatric Patients With Heart Failure
|
N/A | |
Completed |
NCT00370643 -
Glucose Control in Open Heart Surgery
|
Phase 1 | |
Not yet recruiting |
NCT04068116 -
Impact of Ischemic Post-conditioning
|
N/A | |
Enrolling by invitation |
NCT03701997 -
Registry to Monitor Berlin Heart EXCOR® Pediatric VAD as a Bridge to Cardiac Transplantation.
|
||
Completed |
NCT02497950 -
HeartMate 3 ELEVATE™ Registry
|
||
Recruiting |
NCT05934071 -
Effects of the Sodium-glucose Cotransporter 2 Inhibitors+Sacubitril/Valsartan Therapy in Patients With HFrEF.
|
||
Recruiting |
NCT02816047 -
Austrian Wearable Cardioverter Defibrillator Registry
|
||
Completed |
NCT04634708 -
The Use of the EXCOR Active Driving Unit for Mobilization of Pediatric Patients With Ventricular Assist Device Support
|
||
Terminated |
NCT02820441 -
Benefit of One Month Zopiclone Intake on Adaptative Servoventilation Compliance
|
Phase 4 | |
Completed |
NCT01452165 -
Peripheral Artery Disease in Vastmanland
|